Adit Ginde
Concepts (553)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Emergency Service, Hospital | 82 | 2023 | 1842 | 9.250 |
Why?
| Outpatients | 13 | 2023 | 330 | 4.100 |
Why?
| Sepsis | 18 | 2023 | 521 | 4.050 |
Why?
| Critical Illness | 18 | 2023 | 648 | 3.930 |
Why?
| Vitamin D | 19 | 2021 | 341 | 3.270 |
Why?
| Vitamin D Deficiency | 14 | 2021 | 159 | 3.030 |
Why?
| Hospitalization | 40 | 2024 | 1764 | 2.800 |
Why?
| Cholecalciferol | 6 | 2021 | 47 | 2.380 |
Why?
| Physician Assistants | 7 | 2014 | 66 | 2.350 |
Why?
| Hyperoxia | 4 | 2023 | 97 | 2.340 |
Why?
| Emergency Medicine | 13 | 2023 | 239 | 2.340 |
Why?
| Length of Stay | 20 | 2021 | 960 | 2.340 |
Why?
| Patient Discharge | 11 | 2022 | 770 | 2.330 |
Why?
| Adult | 133 | 2024 | 30814 | 2.260 |
Why?
| Humans | 246 | 2024 | 115859 | 2.220 |
Why?
| Hospital Mortality | 17 | 2023 | 779 | 2.190 |
Why?
| Emergency Medical Services | 13 | 2023 | 591 | 2.150 |
Why?
| United States | 85 | 2024 | 12319 | 2.050 |
Why?
| Respiration, Artificial | 10 | 2023 | 525 | 2.030 |
Why?
| Aged | 85 | 2023 | 19292 | 1.930 |
Why?
| Ritonavir | 3 | 2023 | 72 | 1.860 |
Why?
| Middle Aged | 105 | 2024 | 27078 | 1.820 |
Why?
| Hospitals | 9 | 2023 | 585 | 1.820 |
Why?
| Wounds and Injuries | 6 | 2022 | 731 | 1.800 |
Why?
| Patient Transfer | 5 | 2015 | 143 | 1.770 |
Why?
| Laryngoscopy | 7 | 2023 | 92 | 1.730 |
Why?
| Respiratory Tract Infections | 7 | 2021 | 323 | 1.730 |
Why?
| Health Services Accessibility | 11 | 2019 | 771 | 1.690 |
Why?
| Male | 130 | 2023 | 56103 | 1.580 |
Why?
| Influenza, Human | 10 | 2024 | 549 | 1.570 |
Why?
| Oxygen | 8 | 2023 | 837 | 1.540 |
Why?
| Patient Readmission | 5 | 2022 | 609 | 1.510 |
Why?
| Cross-Sectional Studies | 34 | 2023 | 4447 | 1.470 |
Why?
| Female | 127 | 2023 | 60070 | 1.420 |
Why?
| Patient Admission | 7 | 2017 | 175 | 1.310 |
Why?
| Nursing Homes | 3 | 2015 | 136 | 1.290 |
Why?
| Retrospective Studies | 41 | 2023 | 12615 | 1.290 |
Why?
| Laryngoscopes | 6 | 2023 | 38 | 1.270 |
Why?
| Brain Injuries, Traumatic | 2 | 2023 | 302 | 1.250 |
Why?
| Adolescent | 57 | 2024 | 17935 | 1.210 |
Why?
| Rural Health Services | 8 | 2020 | 93 | 1.210 |
Why?
| Influenza Vaccines | 9 | 2024 | 498 | 1.200 |
Why?
| Intensive Care Units | 5 | 2021 | 624 | 1.200 |
Why?
| Vitamins | 7 | 2021 | 151 | 1.200 |
Why?
| Aged, 80 and over | 28 | 2021 | 6434 | 1.190 |
Why?
| Physicians | 10 | 2023 | 777 | 1.170 |
Why?
| Medicaid | 4 | 2015 | 411 | 1.130 |
Why?
| Pneumonia | 5 | 2021 | 576 | 1.120 |
Why?
| Health Care Surveys | 17 | 2020 | 540 | 1.100 |
Why?
| Mass Screening | 7 | 2012 | 1024 | 1.100 |
Why?
| Nurse Practitioners | 4 | 2012 | 105 | 1.080 |
Why?
| Antibodies, Neutralizing | 6 | 2022 | 223 | 1.070 |
Why?
| Referral and Consultation | 6 | 2022 | 647 | 1.040 |
Why?
| Young Adult | 38 | 2024 | 10508 | 1.020 |
Why?
| Stroke | 5 | 2022 | 1016 | 1.020 |
Why?
| Rehabilitation Centers | 2 | 2015 | 32 | 1.010 |
Why?
| Intubation, Intratracheal | 10 | 2023 | 216 | 0.990 |
Why?
| Diabetes Mellitus | 6 | 2011 | 905 | 0.960 |
Why?
| Insurance, Health | 5 | 2020 | 247 | 0.950 |
Why?
| Shock, Traumatic | 1 | 2023 | 16 | 0.880 |
Why?
| Medically Uninsured | 3 | 2014 | 122 | 0.870 |
Why?
| Military Personnel | 4 | 2023 | 526 | 0.840 |
Why?
| Potentially Inappropriate Medication List | 1 | 2022 | 14 | 0.830 |
Why?
| Minority Groups | 2 | 2023 | 232 | 0.820 |
Why?
| Internship and Residency | 8 | 2023 | 957 | 0.810 |
Why?
| Antiviral Agents | 6 | 2023 | 651 | 0.810 |
Why?
| Health Services Needs and Demand | 3 | 2013 | 249 | 0.810 |
Why?
| Airway Management | 1 | 2022 | 60 | 0.800 |
Why?
| Inappropriate Prescribing | 1 | 2022 | 52 | 0.790 |
Why?
| Primary Health Care | 6 | 2019 | 1520 | 0.790 |
Why?
| Treatment Outcome | 24 | 2023 | 9163 | 0.790 |
Why?
| Asthma | 11 | 2012 | 2150 | 0.780 |
Why?
| Pneumonia, Viral | 6 | 2020 | 344 | 0.760 |
Why?
| Coronavirus Infections | 6 | 2020 | 336 | 0.760 |
Why?
| Patient Outcome Assessment | 2 | 2021 | 123 | 0.740 |
Why?
| Critical Care | 5 | 2022 | 480 | 0.730 |
Why?
| Substance Abuse Detection | 1 | 2021 | 62 | 0.720 |
Why?
| Career Choice | 3 | 2010 | 183 | 0.710 |
Why?
| Pandemics | 11 | 2023 | 1337 | 0.710 |
Why?
| Antibodies, Monoclonal | 6 | 2022 | 1264 | 0.700 |
Why?
| Tracheostomy | 1 | 2021 | 99 | 0.700 |
Why?
| Age Factors | 12 | 2019 | 2911 | 0.690 |
Why?
| Personnel Selection | 2 | 2010 | 67 | 0.690 |
Why?
| Resuscitation Orders | 2 | 2019 | 45 | 0.690 |
Why?
| Spine | 1 | 2021 | 141 | 0.670 |
Why?
| Translating | 2 | 2010 | 36 | 0.660 |
Why?
| Warfare | 1 | 2019 | 75 | 0.650 |
Why?
| Triage | 3 | 2020 | 192 | 0.640 |
Why?
| Resuscitation | 1 | 2021 | 248 | 0.640 |
Why?
| Conservative Treatment | 1 | 2018 | 29 | 0.630 |
Why?
| Communication Barriers | 2 | 2010 | 90 | 0.620 |
Why?
| Oxygen Inhalation Therapy | 1 | 2019 | 130 | 0.620 |
Why?
| Brain Ischemia | 3 | 2021 | 298 | 0.610 |
Why?
| Brain Injuries | 1 | 2023 | 451 | 0.600 |
Why?
| Prospective Studies | 17 | 2023 | 6276 | 0.600 |
Why?
| Health Surveys | 4 | 2014 | 447 | 0.600 |
Why?
| Obesity | 4 | 2022 | 2523 | 0.590 |
Why?
| Randomized Controlled Trials as Topic | 12 | 2023 | 1217 | 0.590 |
Why?
| Guideline Adherence | 6 | 2022 | 497 | 0.590 |
Why?
| Sex Factors | 10 | 2019 | 1741 | 0.590 |
Why?
| Databases, Factual | 10 | 2021 | 1137 | 0.570 |
Why?
| Surgical Procedures, Operative | 2 | 2016 | 210 | 0.570 |
Why?
| Language | 2 | 2010 | 257 | 0.560 |
Why?
| Vaccination | 12 | 2024 | 1209 | 0.560 |
Why?
| Professional Autonomy | 2 | 2014 | 25 | 0.560 |
Why?
| Hydroxychloroquine | 3 | 2022 | 55 | 0.560 |
Why?
| Interdisciplinary Studies | 1 | 2016 | 27 | 0.560 |
Why?
| Financing, Organized | 1 | 2016 | 33 | 0.560 |
Why?
| MicroRNAs | 3 | 2017 | 610 | 0.550 |
Why?
| Orthopedics | 1 | 2018 | 125 | 0.550 |
Why?
| Skilled Nursing Facilities | 2 | 2016 | 119 | 0.550 |
Why?
| Healthcare Disparities | 3 | 2012 | 487 | 0.550 |
Why?
| Anti-Infective Agents | 2 | 2022 | 225 | 0.540 |
Why?
| Communication | 2 | 2014 | 749 | 0.540 |
Why?
| Home Care Services | 2 | 2016 | 226 | 0.540 |
Why?
| Pilot Projects | 7 | 2023 | 1379 | 0.520 |
Why?
| Acute Disease | 9 | 2020 | 917 | 0.520 |
Why?
| Boston | 8 | 2010 | 75 | 0.510 |
Why?
| Multiple Trauma | 1 | 2016 | 91 | 0.510 |
Why?
| Emergencies | 3 | 2015 | 150 | 0.510 |
Why?
| Cross Infection | 2 | 2020 | 202 | 0.510 |
Why?
| Severity of Illness Index | 11 | 2022 | 2590 | 0.510 |
Why?
| Insurance Coverage | 3 | 2016 | 204 | 0.500 |
Why?
| Hyperglycemia | 2 | 2009 | 295 | 0.500 |
Why?
| Antibodies, Viral | 4 | 2023 | 527 | 0.500 |
Why?
| Catheterization, Central Venous | 1 | 2016 | 89 | 0.500 |
Why?
| Homes for the Aged | 1 | 2015 | 19 | 0.500 |
Why?
| Double-Blind Method | 12 | 2023 | 1664 | 0.490 |
Why?
| Halfway Houses | 1 | 2014 | 2 | 0.480 |
Why?
| Shock, Septic | 4 | 2018 | 185 | 0.480 |
Why?
| Faculty, Medical | 1 | 2016 | 234 | 0.470 |
Why?
| Nutrition Surveys | 6 | 2011 | 225 | 0.460 |
Why?
| Patient Compliance | 3 | 2008 | 524 | 0.460 |
Why?
| Systemic Inflammatory Response Syndrome | 1 | 2014 | 71 | 0.460 |
Why?
| Opioid-Related Disorders | 1 | 2021 | 422 | 0.450 |
Why?
| Dietary Supplements | 6 | 2021 | 460 | 0.450 |
Why?
| Analgesics, Opioid | 1 | 2021 | 783 | 0.450 |
Why?
| Hospitals, Rural | 2 | 2010 | 31 | 0.450 |
Why?
| Risk Factors | 13 | 2021 | 8715 | 0.450 |
Why?
| Hypoglycemia | 2 | 2008 | 387 | 0.450 |
Why?
| Adenosine Monophosphate | 3 | 2021 | 49 | 0.440 |
Why?
| Urban Health Services | 5 | 2020 | 61 | 0.440 |
Why?
| Point-of-Care Systems | 3 | 2011 | 150 | 0.440 |
Why?
| Betacoronavirus | 3 | 2020 | 254 | 0.440 |
Why?
| Surveys and Questionnaires | 9 | 2017 | 4673 | 0.440 |
Why?
| Alanine | 3 | 2021 | 103 | 0.440 |
Why?
| California | 5 | 2019 | 368 | 0.430 |
Why?
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 666 | 0.430 |
Why?
| Medicare | 3 | 2015 | 666 | 0.430 |
Why?
| International Educational Exchange | 1 | 2012 | 11 | 0.420 |
Why?
| Inflammatory Bowel Diseases | 1 | 2017 | 289 | 0.420 |
Why?
| Renal Dialysis | 1 | 2016 | 371 | 0.420 |
Why?
| International Classification of Diseases | 2 | 2014 | 118 | 0.420 |
Why?
| Odds Ratio | 6 | 2018 | 968 | 0.410 |
Why?
| Health Resources | 1 | 2013 | 122 | 0.410 |
Why?
| Oximetry | 2 | 2023 | 80 | 0.410 |
Why?
| Acute Kidney Injury | 3 | 2018 | 647 | 0.410 |
Why?
| Treatment Failure | 6 | 2022 | 332 | 0.410 |
Why?
| Patient Education as Topic | 4 | 2010 | 685 | 0.400 |
Why?
| Tomography, X-Ray Computed | 3 | 2017 | 2404 | 0.400 |
Why?
| Multivariate Analysis | 6 | 2016 | 1443 | 0.400 |
Why?
| Ambulatory Care | 5 | 2023 | 479 | 0.390 |
Why?
| Hospital Units | 1 | 2011 | 22 | 0.390 |
Why?
| Observation | 1 | 2011 | 50 | 0.390 |
Why?
| Appointments and Schedules | 1 | 2011 | 74 | 0.390 |
Why?
| Time Factors | 14 | 2023 | 6182 | 0.390 |
Why?
| Logistic Models | 7 | 2021 | 1863 | 0.390 |
Why?
| Liability, Legal | 1 | 2011 | 38 | 0.390 |
Why?
| Influenza A Virus, H1N1 Subtype | 2 | 2024 | 139 | 0.390 |
Why?
| Hyperparathyroidism, Secondary | 1 | 2011 | 9 | 0.390 |
Why?
| Patient Safety | 2 | 2016 | 276 | 0.380 |
Why?
| Inpatients | 2 | 2021 | 380 | 0.380 |
Why?
| Inflammation Mediators | 1 | 2014 | 480 | 0.380 |
Why?
| Malpractice | 1 | 2011 | 37 | 0.380 |
Why?
| Colorado | 8 | 2023 | 4122 | 0.380 |
Why?
| Blood Glucose | 3 | 2008 | 1826 | 0.380 |
Why?
| Training Support | 1 | 2010 | 22 | 0.370 |
Why?
| Multicenter Studies as Topic | 5 | 2023 | 249 | 0.370 |
Why?
| Health Care Rationing | 1 | 2010 | 47 | 0.370 |
Why?
| Parathyroid Hormone | 1 | 2011 | 95 | 0.370 |
Why?
| Cohort Studies | 13 | 2023 | 4960 | 0.370 |
Why?
| Personnel, Hospital | 2 | 2020 | 24 | 0.360 |
Why?
| Military Medicine | 2 | 2022 | 93 | 0.360 |
Why?
| Inflammation | 1 | 2021 | 2502 | 0.360 |
Why?
| Digital Rectal Examination | 1 | 2010 | 10 | 0.350 |
Why?
| Electronic Health Records | 3 | 2023 | 805 | 0.350 |
Why?
| Occult Blood | 1 | 2010 | 27 | 0.350 |
Why?
| Patient Care | 1 | 2010 | 103 | 0.350 |
Why?
| Risk Assessment | 8 | 2021 | 2992 | 0.350 |
Why?
| Child | 21 | 2022 | 18537 | 0.350 |
Why?
| Ambulances | 3 | 2023 | 50 | 0.340 |
Why?
| Intrauterine Devices | 1 | 2009 | 24 | 0.330 |
Why?
| Body Mass Index | 4 | 2019 | 1974 | 0.330 |
Why?
| Influenza A Virus, H3N2 Subtype | 3 | 2024 | 40 | 0.320 |
Why?
| Cause of Death | 2 | 2017 | 368 | 0.320 |
Why?
| Socioeconomic Factors | 5 | 2015 | 1088 | 0.320 |
Why?
| South Africa | 3 | 2023 | 162 | 0.310 |
Why?
| Atracurium | 2 | 2019 | 13 | 0.310 |
Why?
| Neuromuscular Blocking Agents | 2 | 2019 | 23 | 0.310 |
Why?
| Mathematics | 1 | 2008 | 100 | 0.300 |
Why?
| Disease Models, Animal | 1 | 2017 | 3587 | 0.300 |
Why?
| Health Knowledge, Attitudes, Practice | 3 | 2015 | 1193 | 0.290 |
Why?
| Magnetic Resonance Imaging | 2 | 2008 | 3072 | 0.290 |
Why?
| Age Distribution | 4 | 2014 | 341 | 0.280 |
Why?
| Decision Support Systems, Clinical | 2 | 2021 | 180 | 0.280 |
Why?
| Acute Lung Injury | 2 | 2022 | 302 | 0.270 |
Why?
| Prevalence | 6 | 2014 | 2270 | 0.270 |
Why?
| Ivermectin | 2 | 2023 | 9 | 0.270 |
Why?
| Community-Acquired Infections | 2 | 2020 | 140 | 0.270 |
Why?
| Cognitive Dysfunction | 2 | 2021 | 280 | 0.270 |
Why?
| Data Collection | 4 | 2014 | 637 | 0.270 |
Why?
| Pulmonary Disease, Chronic Obstructive | 3 | 2009 | 1115 | 0.270 |
Why?
| Emergency Treatment | 3 | 2019 | 115 | 0.260 |
Why?
| Case-Control Studies | 9 | 2022 | 3054 | 0.260 |
Why?
| Pregnancy Complications | 1 | 2010 | 431 | 0.250 |
Why?
| Staphylococcal Infections | 1 | 2009 | 338 | 0.250 |
Why?
| Child, Preschool | 12 | 2019 | 9164 | 0.240 |
Why?
| Hospitals, Urban | 3 | 2016 | 129 | 0.240 |
Why?
| Vaccines, Synthetic | 5 | 2022 | 124 | 0.240 |
Why?
| Disease Progression | 5 | 2021 | 2423 | 0.240 |
Why?
| Physician-Patient Relations | 1 | 2009 | 467 | 0.240 |
Why?
| Fluid Therapy | 2 | 2023 | 122 | 0.240 |
Why?
| Calcitriol | 2 | 2014 | 53 | 0.240 |
Why?
| Choice Behavior | 2 | 2019 | 159 | 0.240 |
Why?
| Diabetic Ketoacidosis | 1 | 2006 | 159 | 0.240 |
Why?
| Medical Audit | 2 | 2018 | 75 | 0.230 |
Why?
| Ambulatory Care Facilities | 3 | 2020 | 211 | 0.230 |
Why?
| Chronic Disease | 3 | 2022 | 1598 | 0.230 |
Why?
| Seasons | 5 | 2024 | 450 | 0.230 |
Why?
| Patient Acceptance of Health Care | 2 | 2020 | 682 | 0.230 |
Why?
| Organ Dysfunction Scores | 2 | 2020 | 39 | 0.230 |
Why?
| Influenza A virus | 1 | 2024 | 91 | 0.220 |
Why?
| Attitude of Health Personnel | 1 | 2010 | 991 | 0.220 |
Why?
| Hypotension | 2 | 2023 | 116 | 0.220 |
Why?
| Receptor, Angiotensin, Type 1 | 1 | 2023 | 21 | 0.220 |
Why?
| Comorbidity | 4 | 2021 | 1476 | 0.220 |
Why?
| RNA, Messenger | 7 | 2023 | 2581 | 0.220 |
Why?
| Androstadienes | 1 | 2023 | 97 | 0.220 |
Why?
| Electronics | 1 | 2023 | 68 | 0.220 |
Why?
| Immunocompromised Host | 2 | 2022 | 197 | 0.220 |
Why?
| Lopinavir | 1 | 2022 | 29 | 0.210 |
Why?
| Respiratory Syncytial Virus, Human | 1 | 2023 | 60 | 0.210 |
Why?
| Urinary Tract Infections | 1 | 2004 | 136 | 0.210 |
Why?
| Renin-Angiotensin System | 1 | 2023 | 72 | 0.210 |
Why?
| Recovery of Function | 3 | 2022 | 576 | 0.210 |
Why?
| Delirium | 1 | 2023 | 66 | 0.210 |
Why?
| Respiratory Syncytial Virus Infections | 1 | 2023 | 97 | 0.210 |
Why?
| Cytokines | 2 | 2014 | 1858 | 0.210 |
Why?
| Health Services Research | 2 | 2016 | 377 | 0.200 |
Why?
| Syncope | 1 | 2022 | 36 | 0.200 |
Why?
| Biomarkers | 7 | 2021 | 3474 | 0.200 |
Why?
| Vasoconstrictor Agents | 2 | 2023 | 113 | 0.200 |
Why?
| Incidence | 3 | 2019 | 2336 | 0.200 |
Why?
| Immunization, Secondary | 1 | 2022 | 82 | 0.200 |
Why?
| Rural Population | 3 | 2016 | 448 | 0.200 |
Why?
| Veterans Health | 1 | 2023 | 165 | 0.200 |
Why?
| Positive-Pressure Respiration | 2 | 2019 | 68 | 0.200 |
Why?
| Polypharmacy | 1 | 2022 | 74 | 0.190 |
Why?
| Hypoxia | 3 | 2023 | 937 | 0.190 |
Why?
| Long Term Adverse Effects | 1 | 2021 | 10 | 0.190 |
Why?
| Malawi | 1 | 2021 | 48 | 0.190 |
Why?
| Academic Medical Centers | 4 | 2020 | 416 | 0.190 |
Why?
| Immunization Programs | 1 | 2023 | 207 | 0.190 |
Why?
| Drug Prescriptions | 1 | 2003 | 241 | 0.190 |
Why?
| Wounds, Penetrating | 1 | 2022 | 72 | 0.190 |
Why?
| Abdominal Pain | 1 | 2022 | 136 | 0.190 |
Why?
| Vasodilator Agents | 1 | 2023 | 309 | 0.190 |
Why?
| Bayes Theorem | 1 | 2022 | 333 | 0.190 |
Why?
| Quality of Health Care | 3 | 2010 | 577 | 0.190 |
Why?
| Work | 1 | 2020 | 17 | 0.190 |
Why?
| Aftercare | 1 | 2022 | 187 | 0.180 |
Why?
| Telecommunications | 1 | 2020 | 16 | 0.180 |
Why?
| Contact Tracing | 1 | 2020 | 16 | 0.180 |
Why?
| Infant | 7 | 2019 | 7992 | 0.180 |
Why?
| Neuromuscular Blockade | 2 | 2019 | 23 | 0.180 |
Why?
| Personnel Turnover | 2 | 2010 | 28 | 0.180 |
Why?
| Video Recording | 4 | 2023 | 147 | 0.180 |
Why?
| Adrenergic beta-Agonists | 2 | 2012 | 129 | 0.180 |
Why?
| Electrocardiography | 1 | 2003 | 560 | 0.180 |
Why?
| Organ Transplantation | 1 | 2022 | 161 | 0.180 |
Why?
| Physical Therapy Modalities | 1 | 2023 | 269 | 0.180 |
Why?
| Abbreviated Injury Scale | 1 | 2019 | 21 | 0.180 |
Why?
| Chi-Square Distribution | 3 | 2012 | 501 | 0.180 |
Why?
| Outpatient Clinics, Hospital | 1 | 2020 | 79 | 0.170 |
Why?
| Respiratory Insufficiency | 1 | 2023 | 292 | 0.170 |
Why?
| Symptom Assessment | 1 | 2020 | 121 | 0.170 |
Why?
| Continuity of Patient Care | 2 | 2012 | 255 | 0.170 |
Why?
| Iraq | 1 | 2019 | 81 | 0.170 |
Why?
| Adrenal Cortex Hormones | 5 | 2021 | 510 | 0.170 |
Why?
| Agkistrodon | 1 | 2019 | 19 | 0.170 |
Why?
| Crotalid Venoms | 1 | 2019 | 31 | 0.170 |
Why?
| Dose-Response Relationship, Drug | 3 | 2020 | 1871 | 0.170 |
Why?
| Afghanistan | 1 | 2019 | 108 | 0.170 |
Why?
| Dantrolene | 1 | 2019 | 5 | 0.170 |
Why?
| Immunoglobulin Fab Fragments | 1 | 2019 | 69 | 0.170 |
Why?
| Neuromuscular Depolarizing Agents | 1 | 2019 | 4 | 0.170 |
Why?
| Malignant Hyperthermia | 1 | 2019 | 7 | 0.160 |
Why?
| Muscle Relaxants, Central | 1 | 2019 | 9 | 0.160 |
Why?
| Succinylcholine | 1 | 2019 | 6 | 0.160 |
Why?
| Lactic Acid | 1 | 2020 | 276 | 0.160 |
Why?
| Antivenins | 1 | 2019 | 55 | 0.160 |
Why?
| Needs Assessment | 3 | 2010 | 320 | 0.160 |
Why?
| Consensus | 1 | 2021 | 531 | 0.160 |
Why?
| Iraq War, 2003-2011 | 1 | 2019 | 151 | 0.160 |
Why?
| Quality Indicators, Health Care | 2 | 2012 | 287 | 0.160 |
Why?
| Injury Severity Score | 2 | 2022 | 460 | 0.160 |
Why?
| Snake Bites | 1 | 2019 | 54 | 0.160 |
Why?
| Afghan Campaign 2001- | 1 | 2019 | 162 | 0.160 |
Why?
| Platelet-Rich Plasma | 1 | 2018 | 23 | 0.160 |
Why?
| Formative Feedback | 1 | 2018 | 23 | 0.160 |
Why?
| Out-of-Hospital Cardiac Arrest | 1 | 2019 | 78 | 0.150 |
Why?
| Time-to-Treatment | 4 | 2021 | 147 | 0.150 |
Why?
| Survivors | 1 | 2021 | 404 | 0.150 |
Why?
| Vaccines | 1 | 2023 | 376 | 0.150 |
Why?
| Cardiovascular Diseases | 1 | 2009 | 1724 | 0.150 |
Why?
| Biological Specimen Banks | 1 | 2018 | 101 | 0.150 |
Why?
| Hospitals, Teaching | 2 | 2011 | 103 | 0.150 |
Why?
| Clinical Competence | 2 | 2010 | 924 | 0.150 |
Why?
| Cognition | 2 | 2023 | 980 | 0.150 |
Why?
| Specimen Handling | 1 | 2018 | 157 | 0.150 |
Why?
| Maryland | 1 | 2017 | 37 | 0.150 |
Why?
| Certification | 3 | 2020 | 90 | 0.150 |
Why?
| Income | 2 | 2008 | 170 | 0.140 |
Why?
| Oxygen Consumption | 1 | 2019 | 572 | 0.140 |
Why?
| Civil Defense | 1 | 2017 | 20 | 0.140 |
Why?
| Assisted Living Facilities | 1 | 2016 | 9 | 0.140 |
Why?
| Environmental Exposure | 1 | 2020 | 380 | 0.140 |
Why?
| Fibroblast Growth Factors | 1 | 2018 | 162 | 0.140 |
Why?
| Executive Function | 1 | 2021 | 372 | 0.140 |
Why?
| Accidental Falls | 2 | 2016 | 151 | 0.140 |
Why?
| Trachea | 3 | 2023 | 233 | 0.140 |
Why?
| Avalanches | 1 | 2016 | 3 | 0.140 |
Why?
| Educational Status | 2 | 2008 | 413 | 0.130 |
Why?
| Mountaineering | 1 | 2016 | 45 | 0.130 |
Why?
| Orthopedic Procedures | 1 | 2018 | 213 | 0.130 |
Why?
| Registries | 2 | 2022 | 1772 | 0.130 |
Why?
| Anesthesiology | 1 | 2016 | 36 | 0.130 |
Why?
| Colitis, Ulcerative | 1 | 2017 | 106 | 0.130 |
Why?
| Predictive Value of Tests | 3 | 2020 | 1813 | 0.130 |
Why?
| Urban Population | 3 | 2010 | 405 | 0.130 |
Why?
| Advance Directives | 1 | 2016 | 69 | 0.130 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2023 | 755 | 0.130 |
Why?
| AIDS Serodiagnosis | 2 | 2012 | 29 | 0.130 |
Why?
| Efficiency, Organizational | 1 | 2016 | 126 | 0.130 |
Why?
| Infant, Newborn | 3 | 2014 | 5084 | 0.130 |
Why?
| Awareness | 1 | 2015 | 91 | 0.120 |
Why?
| Pulmonary Embolism | 1 | 2017 | 182 | 0.120 |
Why?
| Evidence-Based Medicine | 2 | 2016 | 685 | 0.120 |
Why?
| Precision Medicine | 1 | 2018 | 356 | 0.120 |
Why?
| Perioperative Care | 1 | 2016 | 127 | 0.120 |
Why?
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 193 | 0.120 |
Why?
| Neoplasms | 1 | 2008 | 2114 | 0.120 |
Why?
| Cost-Benefit Analysis | 1 | 2017 | 548 | 0.120 |
Why?
| Frail Elderly | 1 | 2015 | 105 | 0.120 |
Why?
| Creatinine | 1 | 2015 | 431 | 0.120 |
Why?
| Hepatopulmonary Syndrome | 1 | 2014 | 25 | 0.110 |
Why?
| Quality Improvement | 1 | 2021 | 958 | 0.110 |
Why?
| Health Care Costs | 1 | 2017 | 384 | 0.110 |
Why?
| Lipopolysaccharides | 1 | 2017 | 832 | 0.110 |
Why?
| Confidence Intervals | 3 | 2010 | 309 | 0.110 |
Why?
| Crohn Disease | 1 | 2017 | 197 | 0.110 |
Why?
| Fluvoxamine | 2 | 2023 | 12 | 0.110 |
Why?
| Patient-Centered Care | 2 | 2016 | 477 | 0.110 |
Why?
| Risk | 2 | 2017 | 829 | 0.110 |
Why?
| Delivery of Health Care | 1 | 2020 | 847 | 0.110 |
Why?
| Pneumonia, Bacterial | 1 | 2014 | 108 | 0.110 |
Why?
| Influenza B virus | 2 | 2024 | 34 | 0.110 |
Why?
| Vaccines, Combined | 2 | 2022 | 46 | 0.110 |
Why?
| Physician's Role | 1 | 2014 | 199 | 0.110 |
Why?
| Headache | 1 | 2013 | 131 | 0.110 |
Why?
| Preventive Health Services | 2 | 2012 | 134 | 0.110 |
Why?
| Anti-Bacterial Agents | 4 | 2018 | 1486 | 0.100 |
Why?
| Hospital Costs | 1 | 2013 | 105 | 0.100 |
Why?
| Combined Modality Therapy | 2 | 2019 | 1127 | 0.100 |
Why?
| Immune System | 1 | 2013 | 173 | 0.100 |
Why?
| Sampling Studies | 1 | 2012 | 95 | 0.100 |
Why?
| Oregon | 1 | 2011 | 66 | 0.100 |
Why?
| Neutrophils | 1 | 2017 | 1171 | 0.100 |
Why?
| Georgia | 1 | 2011 | 59 | 0.100 |
Why?
| Epithelial Cells | 1 | 2017 | 961 | 0.100 |
Why?
| Sex Distribution | 2 | 2013 | 337 | 0.100 |
Why?
| Massachusetts | 1 | 2011 | 137 | 0.100 |
Why?
| Fractures, Bone | 1 | 2016 | 373 | 0.100 |
Why?
| HIV | 1 | 2012 | 209 | 0.090 |
Why?
| Drug Administration Schedule | 3 | 2019 | 724 | 0.090 |
Why?
| Mice, Inbred C57BL | 2 | 2017 | 4779 | 0.090 |
Why?
| Specialization | 1 | 2011 | 117 | 0.090 |
Why?
| Professional Practice Location | 1 | 2010 | 26 | 0.090 |
Why?
| Mice, Knockout | 1 | 2017 | 2608 | 0.090 |
Why?
| Viral Load | 2 | 2023 | 406 | 0.090 |
Why?
| Statistics, Nonparametric | 2 | 2009 | 390 | 0.090 |
Why?
| Patient Protection and Affordable Care Act | 1 | 2011 | 100 | 0.090 |
Why?
| Health Care Reform | 1 | 2011 | 92 | 0.090 |
Why?
| Bias | 2 | 2021 | 181 | 0.090 |
Why?
| Workload | 1 | 2011 | 133 | 0.090 |
Why?
| Legislation as Topic | 1 | 2010 | 4 | 0.090 |
Why?
| Delegation, Professional | 1 | 2010 | 1 | 0.090 |
Why?
| Medically Underserved Area | 1 | 2010 | 80 | 0.090 |
Why?
| Altitude | 1 | 2014 | 409 | 0.090 |
Why?
| Medical Staff, Hospital | 1 | 2010 | 75 | 0.090 |
Why?
| Occupations | 1 | 2010 | 36 | 0.090 |
Why?
| Social Class | 2 | 2009 | 210 | 0.090 |
Why?
| Emergency Nursing | 1 | 2010 | 19 | 0.090 |
Why?
| Practice Patterns, Physicians' | 1 | 2018 | 1182 | 0.090 |
Why?
| Quality of Life | 1 | 2021 | 2390 | 0.090 |
Why?
| Allied Health Personnel | 1 | 2010 | 43 | 0.090 |
Why?
| Motivation | 2 | 2012 | 496 | 0.090 |
Why?
| Infusions, Intravenous | 2 | 2023 | 374 | 0.090 |
Why?
| Sensitivity and Specificity | 1 | 2014 | 1725 | 0.090 |
Why?
| Albuterol | 1 | 2010 | 106 | 0.090 |
Why?
| Mental Health Services | 1 | 2014 | 326 | 0.090 |
Why?
| Geriatric Assessment | 1 | 2011 | 177 | 0.090 |
Why?
| Medical Order Entry Systems | 1 | 2010 | 41 | 0.090 |
Why?
| Algorithms | 1 | 2017 | 1494 | 0.090 |
Why?
| Interprofessional Relations | 1 | 2011 | 258 | 0.080 |
Why?
| Population | 1 | 2009 | 28 | 0.080 |
Why?
| RNA, Viral | 2 | 2023 | 564 | 0.080 |
Why?
| Specialty Boards | 1 | 2009 | 35 | 0.080 |
Why?
| Job Satisfaction | 1 | 2010 | 170 | 0.080 |
Why?
| Schools, Veterinary | 1 | 2008 | 2 | 0.080 |
Why?
| Self Report | 2 | 2023 | 700 | 0.080 |
Why?
| Insulin | 2 | 2009 | 2083 | 0.080 |
Why?
| Nutritional Status | 1 | 2011 | 287 | 0.080 |
Why?
| Forced Expiratory Volume | 1 | 2010 | 521 | 0.080 |
Why?
| Respiratory Syncytial Viruses | 1 | 2008 | 47 | 0.080 |
Why?
| Disease Management | 2 | 2011 | 563 | 0.080 |
Why?
| Fatal Outcome | 1 | 2009 | 286 | 0.080 |
Why?
| Professional Role | 1 | 2010 | 153 | 0.080 |
Why?
| Nurses | 1 | 2010 | 151 | 0.080 |
Why?
| Drug Therapy, Combination | 2 | 2021 | 962 | 0.080 |
Why?
| Smoking Cessation | 1 | 2012 | 378 | 0.080 |
Why?
| Interleukin-10 | 1 | 2010 | 304 | 0.080 |
Why?
| Device Removal | 1 | 2009 | 128 | 0.080 |
Why?
| Mexican Americans | 1 | 2009 | 101 | 0.080 |
Why?
| Animals | 4 | 2019 | 32158 | 0.080 |
Why?
| Mental Recall | 2 | 2021 | 173 | 0.070 |
Why?
| Glucocorticoids | 2 | 2023 | 551 | 0.070 |
Why?
| Immunity, Innate | 2 | 2014 | 735 | 0.070 |
Why?
| Statistics as Topic | 1 | 2008 | 299 | 0.070 |
Why?
| Feasibility Studies | 2 | 2023 | 750 | 0.070 |
Why?
| Health Status Indicators | 1 | 2008 | 155 | 0.070 |
Why?
| Morbidity | 1 | 2008 | 278 | 0.070 |
Why?
| Glucose Tolerance Test | 1 | 2008 | 344 | 0.070 |
Why?
| Data Interpretation, Statistical | 1 | 2009 | 325 | 0.070 |
Why?
| Clinical Trials as Topic | 2 | 2022 | 944 | 0.070 |
Why?
| Forecasting | 1 | 2008 | 332 | 0.070 |
Why?
| RNA | 2 | 2023 | 820 | 0.070 |
Why?
| Administration, Inhalation | 2 | 2023 | 646 | 0.070 |
Why?
| Liver Transplantation | 1 | 2014 | 830 | 0.070 |
Why?
| Papillomavirus Vaccines | 1 | 2009 | 222 | 0.070 |
Why?
| Virus Diseases | 1 | 2008 | 200 | 0.070 |
Why?
| Qualitative Research | 2 | 2022 | 966 | 0.070 |
Why?
| Proportional Hazards Models | 1 | 2009 | 1088 | 0.070 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2009 | 340 | 0.070 |
Why?
| Papillomavirus Infections | 1 | 2009 | 258 | 0.070 |
Why?
| Geography | 1 | 2006 | 183 | 0.070 |
Why?
| History, 21st Century | 1 | 2006 | 164 | 0.070 |
Why?
| Staphylococcus aureus | 1 | 2009 | 386 | 0.060 |
Why?
| Self Care | 1 | 2008 | 354 | 0.060 |
Why?
| History, 20th Century | 1 | 2006 | 275 | 0.060 |
Why?
| Calcium | 1 | 2011 | 1103 | 0.060 |
Why?
| Analysis of Variance | 1 | 2008 | 1227 | 0.060 |
Why?
| Postoperative Complications | 1 | 2015 | 2164 | 0.060 |
Why?
| Lung | 1 | 2017 | 3683 | 0.060 |
Why?
| Prognosis | 2 | 2020 | 3344 | 0.060 |
Why?
| Missouri | 1 | 2004 | 63 | 0.060 |
Why?
| Sex Characteristics | 1 | 2008 | 643 | 0.060 |
Why?
| Patient Acuity | 1 | 2023 | 42 | 0.060 |
Why?
| Angiotensins | 1 | 2023 | 10 | 0.060 |
Why?
| Macrolides | 1 | 2003 | 56 | 0.050 |
Why?
| Calibration | 1 | 2023 | 127 | 0.050 |
Why?
| Remission Induction | 1 | 2023 | 240 | 0.050 |
Why?
| Drug Repositioning | 1 | 2022 | 14 | 0.050 |
Why?
| Angiotensin II | 1 | 2023 | 91 | 0.050 |
Why?
| Nucleocapsid | 1 | 2022 | 17 | 0.050 |
Why?
| Emergency Medical Dispatch | 1 | 2022 | 6 | 0.050 |
Why?
| Immunocompetence | 1 | 2022 | 41 | 0.050 |
Why?
| Medical Futility | 1 | 2021 | 19 | 0.050 |
Why?
| Syndrome | 1 | 2022 | 339 | 0.050 |
Why?
| Information Systems | 1 | 2022 | 61 | 0.050 |
Why?
| Health Promotion | 2 | 2022 | 690 | 0.050 |
Why?
| Pulse Therapy, Drug | 1 | 2021 | 6 | 0.050 |
Why?
| Oligopeptides | 1 | 2023 | 248 | 0.050 |
Why?
| Ligands | 1 | 2023 | 570 | 0.050 |
Why?
| HIV Infections | 2 | 2012 | 2471 | 0.050 |
Why?
| Immunization, Passive | 1 | 2021 | 79 | 0.050 |
Why?
| Antigens, Viral | 1 | 2021 | 177 | 0.050 |
Why?
| Transplant Recipients | 1 | 2022 | 143 | 0.050 |
Why?
| Intention to Treat Analysis | 1 | 2020 | 69 | 0.050 |
Why?
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 5 | 0.050 |
Why?
| Hypoglycemic Agents | 1 | 2008 | 1008 | 0.050 |
Why?
| Personnel Staffing and Scheduling | 2 | 2011 | 80 | 0.050 |
Why?
| Immunization | 1 | 2023 | 402 | 0.050 |
Why?
| Antimalarials | 1 | 2020 | 24 | 0.050 |
Why?
| Immunization Schedule | 1 | 2022 | 184 | 0.050 |
Why?
| Documentation | 1 | 2022 | 169 | 0.050 |
Why?
| Vaccination Coverage | 1 | 2021 | 63 | 0.050 |
Why?
| Follow-Up Studies | 1 | 2009 | 4443 | 0.050 |
Why?
| Health Facilities | 1 | 2021 | 70 | 0.040 |
Why?
| Seroepidemiologic Studies | 1 | 2020 | 141 | 0.040 |
Why?
| Personal Protective Equipment | 1 | 2020 | 50 | 0.040 |
Why?
| Asymptomatic Diseases | 1 | 2020 | 77 | 0.040 |
Why?
| Single-Blind Method | 1 | 2020 | 256 | 0.040 |
Why?
| Recombinant Fusion Proteins | 1 | 2022 | 617 | 0.040 |
Why?
| Practice Guidelines as Topic | 2 | 2022 | 1405 | 0.040 |
Why?
| Education, Medical, Graduate | 1 | 2003 | 378 | 0.040 |
Why?
| ROC Curve | 1 | 2020 | 451 | 0.040 |
Why?
| Ergocalciferols | 1 | 2019 | 11 | 0.040 |
Why?
| Program Evaluation | 1 | 2003 | 841 | 0.040 |
Why?
| Conscious Sedation | 1 | 2019 | 79 | 0.040 |
Why?
| Host-Pathogen Interactions | 1 | 2021 | 296 | 0.040 |
Why?
| Pregnancy | 1 | 2010 | 5555 | 0.040 |
Why?
| Renal Replacement Therapy | 1 | 2018 | 68 | 0.040 |
Why?
| RNA Transport | 1 | 2017 | 22 | 0.040 |
Why?
| Workflow | 1 | 2018 | 138 | 0.040 |
Why?
| Informed Consent | 1 | 2018 | 163 | 0.040 |
Why?
| Controlled Before-After Studies | 1 | 2017 | 14 | 0.040 |
Why?
| Kaplan-Meier Estimate | 1 | 2019 | 816 | 0.040 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.040 |
Why?
| Africa | 1 | 2017 | 99 | 0.040 |
Why?
| Neuropsychological Tests | 1 | 2021 | 918 | 0.040 |
Why?
| Historically Controlled Study | 1 | 2016 | 5 | 0.030 |
Why?
| Gene Knockdown Techniques | 1 | 2017 | 303 | 0.030 |
Why?
| Ghana | 1 | 2015 | 30 | 0.030 |
Why?
| Cell Communication | 1 | 2017 | 280 | 0.030 |
Why?
| Depression | 1 | 2023 | 1145 | 0.030 |
Why?
| Reimbursement, Incentive | 1 | 2015 | 36 | 0.030 |
Why?
| Mortality | 1 | 2017 | 290 | 0.030 |
Why?
| Cathelicidins | 1 | 2014 | 39 | 0.030 |
Why?
| Injections, Intravenous | 1 | 2014 | 204 | 0.030 |
Why?
| Muscle Strength | 1 | 2017 | 278 | 0.030 |
Why?
| Antimicrobial Cationic Peptides | 1 | 2014 | 76 | 0.030 |
Why?
| Nanoparticles | 1 | 2017 | 316 | 0.030 |
Why?
| Clinical Coding | 1 | 2013 | 20 | 0.030 |
Why?
| Internet | 1 | 2017 | 601 | 0.030 |
Why?
| Research Design | 1 | 2018 | 949 | 0.030 |
Why?
| Bed Occupancy | 1 | 2011 | 10 | 0.020 |
Why?
| Domestic Violence | 1 | 2011 | 45 | 0.020 |
Why?
| Resource Allocation | 1 | 2010 | 38 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2017 | 2416 | 0.020 |
Why?
| Salmeterol Xinafoate | 1 | 2010 | 42 | 0.020 |
Why?
| Pamphlets | 1 | 2010 | 24 | 0.020 |
Why?
| Demography | 1 | 2010 | 264 | 0.020 |
Why?
| Tobacco Use Disorder | 1 | 2012 | 237 | 0.020 |
Why?
| Consumer Health Information | 1 | 2010 | 47 | 0.020 |
Why?
| Self Efficacy | 1 | 2012 | 361 | 0.020 |
Why?
| Psychometrics | 1 | 2012 | 615 | 0.020 |
Why?
| Patient Satisfaction | 1 | 2012 | 585 | 0.020 |
Why?
| Teaching | 1 | 2010 | 226 | 0.020 |
Why?
| Research | 1 | 2011 | 398 | 0.020 |
Why?
| Linear Models | 1 | 2009 | 777 | 0.020 |
Why?
| Anti-Asthmatic Agents | 1 | 2010 | 350 | 0.020 |
Why?
| Reproducibility of Results | 1 | 2012 | 2807 | 0.020 |
Why?
|
|
Ginde's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|